Detection of genomic abnormalities in multiple myeloma: The application of FISH analysis in combination with various plasma cell enrichment techniques

American Journal of Clinical Pathology

Volumn 136, Issue 5, 2011, Pages 712-720

  Hartmann, Luise ^a   Biggerstaff, Julie Sanford ^a   Chapman, Douglas B ^a   Scott, Janice M ^a   Johnson, Krystal R ^a   Ghirardelli, Keely M ^a   Fritschle, Wayne K ^a   Martinez, Dolores L ^a   Bennington, Richard K ^a   De Baca, Monica E ^a   Wells, Denise A ^a   Loken, Michael R ^a   Zehentner, Barbara K ^a  

^a HEMATOLOGICS INC   (United States)

Author keywords

Fluorescence in situ hybridization; Multiple myeloma; Plasma cell enrichment; Sensitivity enhancement

Indexed keywords

ARTICLE; BONE MARROW BIOPSY; CELL POPULATION; CELL SELECTION; CHROMOSOME ABERRATION; CHROMOSOME DELETION 13Q; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAGNETIC CELL SORTING; MINIMAL RESIDUAL DISEASE; MONOSOMY 13; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; SCORING SYSTEM; TARGETED MANUAL SCORING; TETRASOMY 11; TRISOMY 11; TRISOMY 3; TRISOMY 5;

BONE MARROW; CHROMOSOME ABERRATIONS; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTIPLE MYELOMA; PLASMA CELLS;

EID: 80355127219     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPF7NFLW8UAJEP     Document Type: Article

References (27)

1. McKenna RW, Kyle RA, Kuehl WM, et al. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:200-208.
2. Inamoto Y, Kurahashi S, Imahashi N, et al. Combinations of cytogenetics and International Scoring System can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation. Am J Hematol. 2009;84:283-286.
3. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3-9.
4. Smadja NV, Bastard C, Brigaudeau C, et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98:2229-2238.
5. Zojer N, Königsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95:1925-1930. (Pubitemid 30151627)
6. Seong C, Delasalle K, Hayes K, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998;91:3366-3371.
7. Neben K, Jauch A, Bertsch U, et al. Combining chromosomal aberrations t(4;14) and del(17p13) with ISS allows a stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica. 2010;95:1150-1157.
8. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210-2221.
9. Klein U, Jauch A, Hielscher T, et al. Chromosomal aberrations +1q21 and del(17)(p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer. 2011;117:2136-2144.
10. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546-1558. (Pubitemid 38235629)
11. Hose D, Reme T, Hielscher T, et al. Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. Haematologica. 2011;96:87-95.
12. Jandl JH. Blood: Textbook of Hematology. New York, NY: Little, Brown; 1996:47.
13. Ciolino AL, Tang ME, Bryant R. Statistical treatment of fluorescence in situ hybridization validation data to generate normal reference ranges using Excel functions. J Mol Diagn. 2009;11:330-333.
14. Paiva B, Almeida J, Perez-Andres M, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom. 2010;78:239-252.
15. Pozdnyakova O, Crowley-Larsen P, Zota V, et al. Interphase FISH in plasma cell dyscrasia: increase in abnormality detection with plasma cell enrichment. Cancer Genet Cytogenet. 2009;189:112-117.
16. Draube A, Pfister R, Vockerodt M, et al. Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement. Ann Hematol. 2001;80:83-89. (Pubitemid 32177953)
17. Cumova J, Kovarova L, Potacova A, et al. Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting. Int J Hematol. 2010;92:314-319.
18. Ahmann G, Chng W, Henderson K, et al. Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. Cancer Epidemiol Biomarkers Prev. 2008;17:666-673. (Pubitemid 351469218)
19. Jourdan M, Ferlin M, Legouffe E, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol. 1998;100:637-646. (Pubitemid 28126093)
20. Chen L, Li J, Xu W, et al. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization. Exp Oncol. 2007;29:116-120. (Pubitemid 47310505)
21. Chen Z, Issa B, Huang S, et al. A practical approach to the detection of prognostically significant genomic aberrations in multiple myeloma. J Mol Diagn. 2005;7:561-565.
22. Shaugnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood. 2000;96:1505-1511. (Pubitemid 30658483)
23. Christensen JH, Abildgaard N, Plesner T, et al. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the region of Southern Denmark. Cancer Genet Cytogenet. 2007;174:89-99. (Pubitemid 46602530)
24. Put N, Lemmens H, Wlodarska I, et al. Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia. Genes Chromosomes Cancer. 2010;49:991-997.
25. Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116:e56-e65. doi:10.1182/blood-2010-04-279596.
26. Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90:1365-1372. (Pubitemid 41503652)
27. Zehentner BK, Fritschle W, Stelzer T, et al. Minimal disease detection and confirmation in hematologic malignancies: combining cell sorting with clonality profiling. Clin Chem. 2006;52:430-437.